Journal of Gynecologic Oncology

19/07/2025

JGO Japan-Korea Principal Editor's Meeting during ASGO 2025
Go for it, JGO!
See you all next time :)

01/12/2024

01/12/2024

01/12/2024

01/12/2024

01/12/2024

Asian Society of Gynecologic Oncology 2024 Meeting
"Close the Gap in Gynecologic Cancer Care in Asia"

07/11/2024

The prognostic value and clinical usage of peritoneal cytology in endometrial cancer are uncertain. This study aimed to determine whether positive cytology is associated with the prognosis for endometrial cancer.

🔗 https://ejgo.org/DOIx.php?id=10.3802/jgo.2025.36.e41

⭐Highlights:
✔ 83,027 patients using the Japanese gynecological cancer registry were analyzed.
✔ Positive peritoneal cytology may be a potential prognostic factor for endometrial cancer.
✔ Positive peritoneal cytology was linked to advanced stages, deep myometrial invasion, lymph node metastasis.
✔ Positive peritoneal cytology were related to poor risk of recurrence

28/10/2024

ASGO invites you to its upcoming Webinar.
We will have Dr. Jack Junjie Chan from National Cancer Centre Singapore speaking on "ADCs in Gyn Cancers - Fresh Data and Trends in 2024."

📅October 31, 2024 (Thursday) at 19:00 KST
Please check your local time: https://shorturl.at/p0Nf5

🔗Click for registration: https://shorturl.at/P7HWv
(Once you register, a web link to the event will be emailed to you automatically)

23/10/2024

How does abnormal expression of p53 impact survival on low grade endometrial endometrioid carcinoma? Check this article:
🔗 https://www.ejgo.org/DOIx.php?id=10.3802/jgo.2024.35.e78

⭐Highlights:
✔️The study investigated outcomes in patients with abnormal p53 expression and stage I, low-grade endometrial endometrioid carcinoma (EEC) at a single institution from January 2019 to December 2022.
✔️Of the 115 patients, 26 had abnormal p53 expression, with a recurrence rate of 19.2% and a mortality rate of 7.7%, while no patients in the normal p53 group experienced recurrence or death due to disease progression.
✔️These findings suggest that abnormal p53 expression is associated with poor prognosis in stage I, low-grade EEC, indicating a need for more aggressive adjuvant therapies for affected patients.

17/10/2024

Biomarkers reflecting real-time response to therapy and recurrence in gynecological cancer are lacking. This article assessed the clinical value of detecting cell-free circulating tumor DNA (ctDNA) mutations in endometrial cancer (EC) and ovarian cancer (OC) patients.

🔗https://ejgo.org/DOIx.php?id=10.3802/jgo.2025.36.e5

⭐Highlights:
✔ Detection of preoperative circulating tumor DNA (ctDNA) mutations was associated with advanced stage, higher CA125, and subsequent disease recurrence.
✔ ctDNA clearance in treatment preceded CA125 normalization.
✔ In patients with recurrent disease who had ctDNA monitoring, ctDNA detection preceded clinical/radiologic/biomarker evidence of recurrence.

09/10/2024

What are the efficacy of long-term efficacy and safety of niraparib asian women with heavily pretreated ovarian cancer?
Check this article:
🔗 https://ejgo.org/DOIx.php?id=10.3802/jgo.2024.35.e114

✔️ Long-term efficacy and safety of niraparib were evaluated in Japanese women with heavily pretreated ovarian cancer.
✔️ Confirmed ORR was 60.0%, with 2 complete and 10 partial responses; median duration of response was 9.9 months.
✔️ Most common TEAEs included anemia (15 patients), nausea (12 patients), and decreased platelet count (11 patients).
✔️ Safety and efficacy findings were consistent with non-Japanese populations; no new safety signals identified.